ClinicalTrials.gg

Program

Four-factor Prothrombin Complex Concentrate

Also written as “BE1116”, “Beriplex® P/N (Kcentra)” and “4-Factor Prothrombin Complex Concentrate (4F-PCC)”.

Its studies are mostly in Wounds and Injuries · Hemophilia B · Blood Coagulation Disorders, led by 2 companies.

Furthest: phase 3, since Jul 1, 20085 company-led studies, 1 open or runningNext primary completion: Apr 6, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL41 open or runningphase 3since Jul 1, 2008Jul 1, 2008Apr 6, 2027phase 3 · NCT07094087
Johnson & Johnson10 open or runningphase 1since Jul 28, 2020Jul 28, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2008First study: phase 3 study in Blood Coagulation DisordersNew to CSLCSL · NCT00708435 · 216 enrolled · United States, Belarus, Bulgaria and more
  2. Dec 4, 2008Phase 3 study in Hemophilia BCSL · NCT00803101 · 176 enrolled · United States, Belarus, Bulgaria and more
  3. Jul 28, 2020Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT04543383 · 52 enrolled · Netherlands
  4. Oct 3, 2022Phase 3 study in Wounds and InjuriesCSL · NCT05568888 · 1,366 enrolled · United States, Australia, United Kingdom
  5. Jul 14, 2025Phase 3 study in Complex Cardiovascular Surgery With Cardiopulmonary BypassCSL · NCT07094087 · 200 planned · United States, Canada, Japan and more

Ahead

  1. Apr 6, 2027Primary completion: phase 3 study in Complex Cardiovascular Surgery With Cardiopulmonary BypassCSL · NCT07094087

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07094087Complex Cardiovascular Surgery With Cardiopulmonary Bypass · United States, Canada, Japan and more3RecruitingCSLApr 6, 2027200
NCT05568888Wounds and Injuries · United States, Australia, United Kingdom3TerminatedCSLOct 29, 20241,366
NCT04543383Healthy · Netherlands1CompletedJohnson & JohnsonJun 7, 202352
NCT00803101Hemophilia B · United States, Belarus, Bulgaria and more3CompletedCSLNov 2012176
NCT00708435Blood Coagulation Disorders · United States, Belarus, Bulgaria and more3CompletedCSLNov 2010216

How it is read

Names in the registry

  • “BE1116”, 2 entries
  • “Beriplex® P/N (Kcentra)”, 2 entries
  • “4-Factor Prothrombin Complex Concentrate (4F-PCC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.